Masha Stromme

Biotech Entrepreneur and CEO of BlackSwanBiotech | Lifelong Anthropologist | Dedicated Mentor & Strategic Advisor in Precision Health

📍 Oslo, Oslo, Norway🔄 Updated September 2026💼 5 investments📅 11 years investing🗓 Last invested Dec 2024
Angel investor🌍 Norway
5
Total investments
0
Early stage
0
Mid stage
0
Late stage
11y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Member of the Board
Aug 2021
At GenieUs, we recognize ALS as a pressing challenge with a high societal cost. With over 70% of ALS patients lacking a known molecular basis, our mission is to unveil the mysteries of this complex disease. We leverage cutting-edge genomics to provide robust in silico genetic understanding through our groundbreaking platform, the Deep integrated Genomic Analysis Platform - DiGAP™. 🔬 This depth of patient genomic profiling will create valuable opportunities for the biopharma industry to develop precision diagnostic and therapeutic solutions for ALS patients. 🌟 The DiGAP™ Deep Insight Report will provide clinicians with valuable insights to guide their therapeutic decisions. 🌐 GenieUs is uniquely positioned to transform the ALS landscape. We're not just pioneers; we're strategists ready to capitalize on the commercial potential of our innovative solutions. Our commitment is to reshape the narrative around ALS and make a lasting impact on patient lives.
Experience · 6 entries
All (6)
Investments (5)
Board (3)
2024
Board Member
Dec 2024
EXACT Therapeutics ("EXACT-Tx") is a clinical-stage biopharmaceutical company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.
2021
Member of the Board
Aug 2021
At GenieUs, we recognize ALS as a pressing challenge with a high societal cost. With over 70% of ALS patients lacking a known molecular basis, our mission is to unveil the mysteries of this complex disease. We leverage cutting-edge genomics to provide robust in silico genetic understanding through our groundbreaking platform, the Deep integrated Genomic Analysis Platform - DiGAP™. 🔬 This depth of patient genomic profiling will create valuable opportunities for the biopharma industry to develop precision diagnostic and therapeutic solutions for ALS patients. 🌟 The DiGAP™ Deep Insight Report will provide clinicians with valuable insights to guide their therapeutic decisions. 🌐 GenieUs is uniquely positioned to transform the ALS landscape. We're not just pioneers; we're strategists ready to capitalize on the commercial potential of our innovative solutions. Our commitment is to reshape the narrative around ALS and make a lasting impact on patient lives.
2019
RemovAid
Board Member
Aug 2019
PubGene Inc
Investor
Mar 2019
2015
Salamander Invest AS
Salamander Invest
Oct 2015
Show all 6 entries ↓
Investment activity
2015–2024 · 5 investments
20151201922021120241
Recent (last 2 years)Earlier